Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Nilsine Partners LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,519 shares of the biopharmaceutical company’s stock, valued at approximately $700,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares during the period. Walleye Capital LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $4,936,000. AQR Capital Management LLC increased its holdings in Catalyst Pharmaceuticals by 87.1% in the 2nd quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock worth $7,565,000 after buying an additional 227,321 shares during the period. Allspring Global Investments Holdings LLC raised its position in Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after buying an additional 217,956 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in Catalyst Pharmaceuticals by 47.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock valued at $9,577,000 after acquiring an additional 200,370 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $22.84 on Wednesday. The stock has a market capitalization of $2.72 billion, a PE ratio of 19.36, a P/E/G ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.12 and a fifty-two week high of $24.27. The company has a fifty day moving average of $21.86 and a two-hundred day moving average of $20.61.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock valued at $1,754,140 over the last 90 days. Corporate insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CPRX. Stephens started coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company. HC Wainwright lifted their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.